LEXICON PHARMACEUTICALS, INC.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-06-30; filed 2026-08-06.
0001062822-26-000117
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2026-09-30; filed 2026-11-05.
0001062822-26-000128
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 46 previous paragraphs and 47 current paragraphs.
44 unchanged; 2 reworded; 1 added; 0 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (1)
Current report
•We plan to resubmit our NDA for ZYNQUISTA in type 1 diabetes based on patient exposure and safety data from an investigator-initiated study of ZYNQUISTA being conducted by a third party. The FDA may determine that the design, conduct or data from such study are not sufficient to support resubmission of the NDA or regulatory approval in type 1 diabetes.
Reworded paragraphs (2)
Previous wording
•We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.
Current wording
•We are subject to certain healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.
Previous wording
•If we do not effectively manage our affirmative and restrictive covenants under the Oxford Term Loans, our financial condition and results of operations could be adversely affected.
Current wording
•If we do not effectively manage our affirmative and restrictive covenants under the Hercules Term Loan, our financial condition and results of operations could be adversely affected.